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ABSTRACT:
p53 plays an important role in the regulation of the cell cycle, DNA repair, and apoptosis 
and is an attractive cancer therapeutic target. Mdm2 and MdmX are recognized as 
the main p53 negative regulators. Although it is still unknown why Mdm2 and MdmX 
both are required for p53 degradation, a model has been proposed whereby these two 
proteins function independent of one another; Mdm2 acts as an E3 ubiquitin ligase that 
catalyzes the ubiquitination of p53 for degradation, whereas MdmX inhibits p53 by 
binding to and masking the transcriptional activation domain of p53, without causing its 
degradation. However, Mdm2 and MdmX have been shown to function collaboratively. 
In fact, recent studies have pointed to a more important role for an Mdm2/MdmX co-
regulatory mechanism for p53 regulation than previously thought. In this review, we 
summarize current progress in the field about the functional and physical interactions 
between Mdm2 and MdmX, their individual and collaborative roles in controlling p53, 
and inhibitors that target Mdm2 and MdmX as a novel class of anticancer therapeutics.
INTRODUCTION
The p53 tumor suppressor plays a pivotal role in 
regulating cellular processes including cell cycle arrest, 
apoptosis, cell metabolism and senescence. Mutation of 
the TP53 gene or inactivation of the p53 signaling pathway 
occurs at a high frequency in many human tumors, 
suggesting that p53 plays a critical role in preventing 
normal cells from becoming cancerous. p53 is a stress-
inducible protein; it is inactive under normal physiological 
conditions and activated in response to various types of 
stresses such as DNA damage and ribosomal stress [1]. 
Activated p53 can either induce cell cycle arrest and 
inhibit cell growth or promotes cell apoptosis depending 
on different type of stress and the cellular context. 
Multiple mechanisms have been revealed to collectively 
accomplish the regulation of p53 activity [2,3], which 
ultimately determines the selectivity of p53 for specific 
transcriptional targets, resulting in precise control of the 
p53 activity.  
p53 is the most frequently inactivated tumor 
suppressor gene in human cancer. Clinical studies have 
shown that p53 is mutated in approximately 50% of human 
cancers. Mdm2 and MdmX (also known as MDM4) are 
two structurally related proteins that play a critical role 
in downregulating p53 activity in embryonic cells and 
stem cells under normal conditions [4]. Therefore, the 
amplification and/or aberrant expression of Mdm2 and 
MdmX occur in a number of tumors of diverse origin, 
especially in tumors that retain wild-type p53.
Mdm2 (murine double minute 2) was discovered on 
double minute chromosomes in a derivative cell line of 
NIH-3T3 cells [5,6]. Mdm2 belongs to the family of E3 
ubiquitin ligases that contain a RING [really interesting 
new gene] domain [7] and serves as the major E3 ubiquitin 
ligase for p53 degradation. Several studies have illustrated 
the importance of Mdm2 in the control of p53 activity. The 
mechanism by which Mdm2 suppresses p53 has classically 
been thought to occur by two distinct ways: by binding to 
the N-terminal domain of p53 and masking p53’s access to 
transcriptional machinery, and by ubiquitinating p53 and 
targeting it for proteasomal degradation [8-11]. However, 
recent research has shown that Mdm2-p53 binding alone 
in the absence of Mdm2 E3 ubiquitin ligase activity is 
insufficient to suppress p53 activity [12]. 
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gene that is closely related to Mdm2 [13,14]. Similarly 
to Mdm2, MdmX possesses a p53 binding domain at its 
N-terminus and a RING finger domain at its C-terminus 
through which it heterodimerizes with Mdm2. However, 
unlike Mdm2, MdmX does not have appreciable ubiquitin 
ligase activity. Because of its sequence similarity with 
Mdm2 and its ability to inhibit p53-induced transcription 
when overexpressed, MdmX has been hypothesized to act 
as a negative regulator of p53 through physical binding 
[15]. 
MODELS FOR THE REGULATION OF P53 
BY MDM2 AND MDMX
Genetic evidences have shown that Mdm2 and 
MdmX are the two essential negative regulators of 
p53, since the concomitant deletion of p53 can rescue 
the embryonic lethality caused by the deletion of either 
Mdm2 or MdmX. The fact, neither Mdm2 nor MdmX can 
compensate for one another in vivo to inhibit p53 suggests 
that Mdm2 and MdmX perform critical, non-overlapping 
functions in p53 suppression. The requirement of both 
Mdm2 and MdmX raises the question as to why p53 
needs two highly similar regulators. A proposal has been 
put forward whereby these two homologous proteins 
can function independently: Mdm2 functions as an E3 
ubiquitin ligase that catalyzes the ubiquitination of p53, 
MdmX, and itself for proteosomal degradation [16-18], 
whereas MdmX functions mainly by binding to and 
masking the transcriptional activation domain of p53. 
Mdm2 and MdmX physically interact with and 
functionally affect each other. Mdm2 can form a 
homodimer in vitro, but it is also capable of forming a 
more stable heterodimer with MdmX through their 
RING domains [19,20]. In vitro transfection studies have 
indicated that MdmX stabilizes Mdm2 by interfering with 
Mdm2 autoubiquitination. However, MdmX has also been 
reported to be ubiquitinated and degraded by Mdm2 [18]. 
Other studies have shown that MdmX is able to inhibit 
Mdm2-mediated p53 degradation by competing with 
Mdm2 for p53 binding resulting in the accumulation of 
p53 [20-22].
Many lines of evidence point to an intricate 
interaction that exists between Mdm2 and MdmX in 
p53 regulation [23-27]. Mdm2 and MdmX proteins are 
found to exist in cells predominantly in the form of a 
heteroduplex [25], and structural studies have predicted 
that the formation of an Mdm2-MdmX heteroduplex is 
structurally favored over the formation of homoduplexes 
of either protein [28]. It has been shown that Mdm2 
alone is a relatively inefficient E3 ubiquitin ligase [25], 
but becomes more efficient at ubiquitinating p53 after 
heterodimerization with MdmX [26]. A previous genetic 
study in the development of the mouse central nervous 
system (CNS) has revealed a synergistic role between 
Mdm2 and MdmX, as well as independent functions of 
Mdm2 and MdmX for p53 inhibition. In this study, mice 
lacking Mdm2 in the CNS developed hydranencephaly at 
embryonic day 12, whereas mice in which MdmX was 
deleted in the CNS showed a proencephaly phenotype 
at embryonic day 17.5. Interestingly, the simultaneous 
deletion of both genes resulted in an even earlier and 
more severe CNS phenotype. All of these phenotypes 
were rescued by the concomitant deletion of p53. These 
observations strongly support a synergistic relationship 
between Mdm2 and MdmX in the inhibition of p53 
activity during the development of the CNS [29]. Based 
on both in vitro and in vivo studies, another, perhaps more 
convincing model was proposed in which Mdm2 and 
MdmX work together to control p53 activity [30,31].
In order to determine whether Mdm2-p53 binding 
alone is sufficient to suppress p53 activity, or whether 
Mdm2-medi  ated ubiquitination is also required in that 
regard, Itahana et al. [12] generated knock-in mice 
harboring a single point muta  tion (C462A) in one of 
the zinc-coordinating residues in the C-terminal RING 
domain of Mdm2 that is critical for the E3 ubiquitin ligase 
activity of Mdm2. The homozygous C462A mutation was 
embryonic lethal and the lethality was rescued by the 
concomitant deletion of p53, providing evidence that the 
Mdm2 RING domain is required for the regulation of p53 
activity in vivo. This study used an inducible p53ER system 
that allowed the investigators to induce the expression of 
p53 ex vivo in mouse embryonic fibroblast (MEF) cells 
to study the interactions of p53 in the Mdm2 mutant 
background. Upon induction of p53 in MEF cells, Itahana 
et al. demonstrated that the Mdm2 RING mutant protein, 
although deficient in the ability to ubiquitinate p53, is 
fully capable of binding to p53 proving that Mdm2 cannot 
suppress p53 transcriptional activity through binding 
alone. However, the authors also showed that the C462A 
mutation alters the structure of the Mdm2 RING domain 
to the extent that the Mdm2 C462A mutant is unable to 
heterodimerize with MdmX. Therefore, the study cannot 
explain whether Mdm2 and MdmX interaction is required 
for p53 suppression. 
Recently, two studies using MdmX RING domain 
mutant knock-in alleles demonstrated that the RING 
domain of MdmX, like that of Mdm2, is also critical 
for regulating p53 activity during early embryogenesis 
[32,33]. In the Huang et al. study, mice harboring an 
MdmX C462A mutation in one of the critical zinc-
coordinating residues of the RING domain died at 
approximately day 9.5 of embryonic development as the 
result of an increase in apoptosis and a decrease in cell 
proliferation. The concomitant deletion of p53 completely 
rescued the embryonic lethality of the MdmX C462A 
mutation [32]. Importantly, the authors showed that the 
MdmX C462A mutant protein does not bind to Mdm2, 
yet it retains the ability to bind to p53 to the same degree 
as wild-type MdmX. These results indicate that even 
though both Mdm2 and MdmX are fully capable of Oncotarget 2012; 3:  228-235 230 www.impactjournals.com/oncotarget
binding to p53 individually, the disruption of the Mdm2-
MdmX heterocomplex causes p53 activation in vivo. In a 
similar study performed by Pant et al., the authors used 
a tamoxifen-based Cre-inducible MdmX ΔRING allele to 
investigate the role of Mdm2-MdmX heterodimerization 
in Mdm2 and p53 regulation. They found that although the 
heteroduplex is essential during embryonic development, 
heterodimerization is dispensable during the adult life of 
the mouse. Together, these studies provide compelling 
evidence that the action of the heterodimer of Mdm2 
and MdmX, and not necessarily the independent action 
of either protein is crucial to the appropriate control of 
p53. However, these studies cannot answer a remaining 
question as whether the Mdm2 E3 ubiquitin ligase 
function is still required for p53 suppression, because 
the Mdm2 RING mutation simultaneously disrupts 
its E3 ligase function and its binding to MdmX, and 
because  in vitro studies have shown that Mdm2 by 
itself is a relatively weak E3 for p53 degradation and its 
heterodimerization with MdmX enhances its E3 activity 
[25,26]. Thus, the generation and analysis of mutations 
that block the ubiquitin ligase activity but do not affect the 
heterodimerization between Mdm2 and MdmX in vivo, if 
technically possible, would be essential for understanding 
the importance of the in vivo cooperation between Mdm2 
and MdmX. 
THE MDM2/MDMX RATIO DETERMINES 
P53 STABILITY AND ACTIVITY
Although Mdm2 and MdmX have a synergistic 
relationship that effectively inhibits p53, as discussed 
above, Mdm2 and MdmX also have independent 
roles in the regulation of p53. MdmX can inhibit p53 
transcriptional activity by interfering with the ability of 
p53 to interact with the basal transcription machinery, 
while Mdm2 can target p53 for degradation. Several 
studies have reported that elevated MdmX levels stabilize 
p53 by inhibiting Mdm2-mediated p53 degradation 
without interfering significantly with Mdm2-dependent 
p53 ubiquitination [21,22,34,35]. Transfection studies 
have also provided evidence that MdmX can stabilize 
Mdm2 by interfering with auto-ubiquitination and 
degradation of Mdm2 [34]. Conversely, results from 
Linares et al. have shown that MdmX stimulates Mdm2-
mediated ubiquitination of p53, as well as Mdm2 self-
ubiquitination in vitro [26]. These inconsistent data reflect 
the complex relationship between Mdm2 and MdmX 
and are often difficult to reconcile because of the nature 
of in vitro overexpression studies. Quantitative analysis 
has demonstrated that the level of endogenous MdmX is 
present at different proportion to that of Mdm2 in several 
types of human cell lines [36]. This observation might 
well account for the discrepancies when trying to examine 
the effect by altering the MdmX abundance in various in 
vitro studies and also indicates the relative level of Mdm2 
and MdmX is crucial for controlling p53 stability and 
activity, which was further demonstrated by the recent 
crystal structures studies. Linker et al. revealed that the 
primary and secondary interfaces in Mdm2 homodimers 
or Mdm2/MdmX heterodimers are crucial for the binding 
of ubiquitin E2 enzyme and ubiquitylation of the subunit. 
Because Mdm2 homodimers have two primary and 
secondary interfaces for ubiquitin E2 enzyme binding 
and the E2 enzyme can be recruited by either monomer, 
which will lead to the ubiquitylation of the other subunit. 
However, in the Mdm2/MdmX heterodimer, only Mdm2 
can provide the primary E2 interaction site while the 
secondary interface will be provided by MdmX, which 
will not cause the ubiquitylation and degradation of 
Mdm2. Therefore, the ratio of Mdm2/MdmX can be used 
to explain Mdm2 status in different situations: Mdm2 
will form homodimer and degrade by itself through 
ubiquitination if the ratio is high, on the contrary, Mdm2 
will be stabilized if the ratio is low [37].
Both  in vivo and in vitro experiments have 
demonstrated that p53 can bind to p53-responsive 
elements located within the Mdm2 gene and promote 
its transcription thereby set up a negative feedback 
regulatory loop [38,39], while in contrast p53 cannot 
transactivate MdmX. Because of this, the protein level 
of Mdm2 fluctuates widely upon p53 activation, whereas 
since MdmX is not a p53 transcriptional target, the level 
of MdmX remains relatively constant. Thus, the stress-
induced up-regulation of p53 increases the levels of 
Mdm2 thereby modulating the ratio of Mdm2 to MdmX 
and serving as a negative feedback loop by which p53 can 
regulate itself. When the level of MdmX is higher than 
the level of Mdm2, MdmX will inhibit Mdm2-mediated 
p53 degradation resulting in the stabilization of the 
level of Mdm2 through the stabilization of p53. In this 
proposed feedback loop, MdmX acts as a sensor of the 
concentration of Mdm2 and controls the balance between 
Mdm2 and p53.
MDM2 AND MDMX IN P53 UBIQUITINATION
It has been widely accepted that Mdm2 antagonizes 
p53 by promoting its ubiquitination and proteasome-
dependent degradation [8,10]. In addition to the 
polyubiquitin-dependent degradation of p53, Mdm2 
can also promote monoubiquitination of p53; this does 
not directly cause p53 degradation, but can promote the 
export of p53 from the nucleus to the cytoplasm especially 
to the mitochondria and further promote other kinds of 
modification of p53 [40,41]. In vitro studies have shown Oncotarget 2012; 3:  228-235 231 www.impactjournals.com/oncotarget
that DNA damage can destabilize Mdm2 by means of 
autoubiquitination [39,42] and Mdm2 ubiquitinates 
MdmX to mark it for proteasomal degradation [43,44]. 
As discussed above, MdmX does not have appreciable 
ubiquitin ligase activity, but MdmX has been proposed 
to inhibit p53 by binding to the N-terminal transcription 
activation domain of p53 [13]. This binding inhibits p53 
activation by hampering the interaction p53 with p300, 
as acetylation of p53 by p300 can lead to p53 activation 
and increased transcriptional activity [45]. Consistently, 
increased endogenous p53 acetylation level is observed 
in MdmX-null cells. Furthermore, it has been reported 
that several lysine residues at the C-terminal region 
of p53 involved in the acetylation are also the same 
sites of Mdm2-mediated ubiquitination [46]. Thus, it is 
conceivable that MdmX might indirectly stimulate the 
Mdm2-mediated ubiquitination of p53 through decreasing 
the acetylation. Together with the observation that the 
Mdm2-MdmX heterodimer is a more effective E3 ligase 
for p53 ubiquitination than Mdm2 alone [26], these data 
support a model in which the Mdm2-MdmX complex 
is more efficient in targeting p53 for ubiquitination and 
degradation. 
Ubiquitin-conjugating enzymes (E2s) have a 
dominant role in determining which of the lysine 
residues are used for polyubiquitination. Like many 
other RING domain proteins, the Mdm2 RING domain 
can promote the transfer of ubiquitin molecules from an 
E2 conjugating enzyme directly to the lysine residues 
of the target substrates [47]. Because the E2 enzyme 
decides the type and length of ubiquitin linkage [48], it 
is important to identify which E2s are recruited to the 
Mdm2-MdmX complexes. In vitro studies have shown 
that UbcH5 functions as an E2 enzyme for Mdm2-induced 
p53 ubiquitination and degradation [49]. Whether UbcH5 
functions in vivo as the main E2 for Mdm2, or whether 
there are other E2 enzymes that interact with Mdm2 
remains to be determined. A recent study [50] has shown 
that E2 enzyme in the absence of the appropriate E3 
ubiquitin ligase is sufficient to promote the ubiquitination 
of the substrate. Based on the results of this study, the 
authors conclude that the main function of E3 ligases 
include: to specify the lysines to be ubiquitinated, to 
specify the conformation of ubiquitination, to specify 
mono versus polyubiquitination, and to define the target 
region on the substrate to be ubiquitinated.
PHOSPHORYLATION OF MDM2 AND 
MDMX 
In addition to ubiquitination as a mechanism of 
controlling Mdm2 and MdmX, the activity of these 
proteins depends on their phosphorylation status. A 
number of kinases have been reported to phosphorylate 
Mdm2 and MdmX at different residues. DNA damage 
stimulates activation of multiple kinases including ataxia 
telangiectasia mutated (ATM) [51], checkpoint kinases 
1 and 2 (Chk1 and Chk2) [52], DNA-dependent protein 
kinase (DNA-PK), and c-Abl kinase, which leads to 
the phosphorylation of both Mdm2 and MdmX [53,54]. 
Evidence supports the idea that the phosphorylation 
of Mdm2 by ATM inhibits Mdm2 RING domain 
homodimerization, which prevents the polyubiquitination 
of p53 [55]. In addition, ATM and Chk2 have been shown 
to phosphorylate and destabilize MdmX [56-59]. Another 
protein that has been shown to regulate Mdm2 and MdmX 
phosphorylation status is Wip1, which is a phosphatase 
that can specifically dephosphorylate Mdm2 at Ser395 and 
MdmX at Ser403 increasing their stability and inhibiting 
p53 activity [60,61]. 
The dimerization of Mdm2 and MdmX and 
Mdm2’s E3 ligase function also appear to be regulated 
by phosphorylation. In an MdmX3SA (Ser-341, -367 and 
-402 to alanine) knock-in mouse model, Mdm2 retains the 
ability to bind to MdmX, but is significantly reduced in its 
capacity to degrade MdmX, resulting in an increase in the 
concentration of Mdm2-MdmX heterodimers [62]. Thus, 
the observed defect in p53 stabilization in MdmX3SA 
mice could be due to the presence of high levels of 
Mdm2-MdmX complexes. This study also found an 
approximately 50% reduction in the basal p53 activity in 
MdmX3SA mice indicating that the stoichiometric balance 
between Mdm2 and MdmX is crucial for p53 activation 
and its response to DNA damage stress in vivo. 
INHIBITORS TARGETING MDM2 AND 
MDMX
Although approximately 50% of cancers harbor 
p53 mutations, the other 50% of cancers retain WT p53, 
yet they remain uninhibited by the tumor suppression 
activity of p53. This is generally accomplished through the 
overexpression of Mdm2 or MdmX by gene amplification 
or mutation. It has been accepted, at least theoretically, 
that reactivation or restoration of the p53 function in 
tumors is a promising cancer therapeutic strategy. Some 
proposed strategies include repressing the expression 
of Mdm2, blocking the p53-Mdm2 interaction, and 
inhibiting the ubiquitin ligase activity of Mdm2 [63,64]. 
For example, Nutlin, a small molecule that inhibits Mdm2, 
can trigger cell-cycle arrest and apoptosis and exhibits 
antitumor  efficacy  in  a  murine  xenograft  model  [65]. 
Several studies also revealed that rational combination of 
Nutlin-3a and other drugs could potentiate chemotherapy 
with mitotic inhibitors against cancer and protect normal 
cells from cytostatic agent [66,67]. However, still several 
issues have been raised from studies of Nutlin. One of 
them is the high toxicity of inhibiting Mdm2 by Nutlin. 
Studies in mice indicate that Mdm2 loss leads to induction 
of p53 activation and p53-dependent pathologies in 
both proliferating and quiescent cells, such as erythroid 
progenitor cells, neurons and smooth muscle cells [68]. Oncotarget 2012; 3:  228-235 232 www.impactjournals.com/oncotarget
Another limitation with Nutlin is that although Nutlin 
kills cancer cells that express elevated Mdm2, tumor cells 
overexpressing MdmX have poor response to Nutlin due 
to its low binding affinity for MdmX compared to Mdm2. 
As an alternative route for p53 inhibition, overexpression 
of MdmX in tumor cells has been observed. This will 
decrease the efficacy for anti-Mdm2-based cancer therapy. 
Therefore, the development of compounds targeting 
both Mdm2 and MdmX in tumors retaining WT p53 has 
become a promising therapeutic goal.
Recently, Bernal et al. [69] showed in both in vitro 
and in vivo experiments that a ‘‘stabilized alpha-helix’’ 
of p53 peptide, SAH-p53-8, preferentially inhibits the 
binding of p53 with MdmX and reduces cancer cell 
viability, thereby overcomes MdmX-mediated cancer 
resistance. SAH-p53-8 is derived from the so-called 
‘‘stapled’’ peptides SAH-p53 that was designed based on 
the peptide sequence of the p53 transactivation domain. 
This peptide show protease resistant combined with 
increased cellular uptake properties due to a chemical 
designed strategy termed “hydrocarbon stapling”, which 
can mimic the biological function of the nature α-helical 
structure. Co-immunoprecipitation experiments indicate 
that this peptide can bind to both Mdm2 and MdmX 
within the cells. Although SAH-p53-8 exhibits a 25-fold 
greater binding preference for MdmX over Mdm2, it has 
been shown to have the ability to kill cancer cells that 
overexpress Mdm2, MdmX, or both of the proteins. More 
importantly, SAH-p53-8 has been shown to efficiently 
induce a tumor-suppressive response in vivo. The study 
provides a clue to reactivate p53 tumor suppressor 
function by synergistically applying Mdm2 and MdmX 
inhibitors in cancer cells, and affords new therapeutic 
opportunities for simultaneously inhibiting both Mdm2 
and MdmX to restore p53 using drug combinations or 
dual-inhibitory drugs [70-72]. Thus, efficient rescue of 
p53 by pharmacological drugs targets Mdm2-MdmX 
hetero-oligomers is conceptually viable.
CONCLUDING REMARKS
Over the past decade, considerable progress has 
been made towards understanding the regulation of p53 
by Mdm2 and MdmX, and much of which has come 
from data obtained from various mouse models. It is 
generally accepted that the ubiquitination of p53 is a 
fundamental mechanism of p53 control and that Mdm2 
is the principal p53 ubiquitin ligase [36,73]. A study of 
an Mdm2 RING finger mutant knockin mouse model 
[12] has shown that Mdm2 is in fact not regulated by 
autoubiquitination in vivo, nor is it capable of blocking 
p53 activity by binding alone. This is consistent with 
an earlier report that small molecules that inhibit the 
E3 ubiquitin ligase activity of Mdm2 can activate p53 
[10,74]. However, the exact mechanism underlying the 
degradation of p53, the regulation of the RING domain 
of Mdm2, and the role of MdmX in this process is still 
unclear. Therefore, it is essential to fully understand how 
the RING domain of Mdm2 regulates p53; whether it is 
an independent mechanism whereby Mdm2 modifies p53 
directly by ubiquitination and degradation, or whether 
Mdm2 requires MdmX binding in order to regulate p53 
activity by the Mdm2-MdmX heterodimer. Recent studies 
using MdmX RING mutant knockin mouse models can 
account for part of the story. They show that Mdm2 with 
an intact RING domain and intrinsic E3 ligase activity 
are not sufficient for the inhibition of p53 activity in the 
absence of interaction with MdmX. These studies provide 
the first in vivo evidence that the association of Mdm2 
with MdmX, but not the Mdm2 E3 ligase activity, is 
necessary for p53 control, at least in the developmental 
stage of mice, which is consistent with previous data based 
on in vitro experiments. Nevertheless, several questions 
still remain: Whether degradation must occur in order for 
p53 to be rendered inactive, or whether ubiquitination 
without degradation is sufficient for the inhibition of p53, 
how the Mdm2-MdmX heterodimer enables Mdm2 to 
be more efficiently ubiquitinating p53, and whether the 
Mdm2-MdmX heterodimer affects p53 ubiquitination. 
Although much has already been learned about the 
regulation of p53 by Mdm2 and MdmX, much still 
remains unknown. Crystal structure studies are needed to 
further understand at the molecular level how exactly the 
Mdm2-MdmX-p53 ternary complex is formed and why 
the Mdm2-MdmX complex is a more efficient E3 ligase 
complex than Mdm2 alone. The histone acetyltransferase 
PCAF [75] has been identified as an E3 ubiquitin ligase 
that mediates the degradation of Mdm2. However, 
can Mdm2 be ubiquitinated and degraded by an as yet 
undefined E3 ubiquitin ligase? Under which circumstances 
is  p53  monoubiquitinated  and  polyubiquitinated?  Do 
Mdm2 and MdmX have additional functions independent 
of regulating p53? The answers to these questions will be 
important for understanding the importance of the Mdm2-
MdmX heterodimer in tumorigenesis and for determining 
the feasibility of the Mdm2-MdmX heterodimer as a target 
for cancer therapy. 
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